Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $274.8452W HIGH $436.24
Volume
2.08 M
Value Traded
339.65 M
Short % Float
2.47%
+4.61%Week
-0.92%1 Month
-2.93%3 Month
+30.57%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
89.50 B
EPS (TTM)
22.88
P/E Ratio
18.03
Ent. Value
83.71 B
Total Shares
216.89 M
Float Shares
216.36 M
Insiders
0.23%
Institutions
94.73%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ELV Catalyst Timeline
Dated clinical, regulatory and corporate events for Elevance Health, Inc.
Past FDA Catalysts and PDUFA Decisions
How ELV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$63M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 68%
Large Pharma(rank 449 of 660)
Percentile Rank
Elevance Health, Inc. faces pipeline headwinds (30/100), with $63M risk-adjusted pipeline value, led by rAAV2tYF-CB-hRS1 in X-linked Retinoschisis (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| rAAV2tYF-CB-hRS1 Monoclonal antibodyCompletedNCT02416622 | X-linked Retinoschisis | Phase 1 | COMPLETED | 27 | May 9, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every ELV program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BOUDREAUX GAILDirector, Officer (President and CEO) | Buy | 680 169,931 held | $366.41 | 07/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ELV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.8 % (14.3 %) | 44.36 M | 114.70 K |
ELV Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ELV ranks across every disease it competes in
Competitive Position is a premium feature
See how ELV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialELV News
-ELV
Oct 5, 2026Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
Elevance Health will announce its third quarter 2026 financial results on October 21, 2026. A conference call is scheduled for 8:30 a.m. EDT to discuss these results and the company's future outlook. Participants are encouraged to join the call at least 15 minutes early.
Read more →-ELV
Oct 1, 2026Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
Elevance Health has announced its 2027 Medicare Advantage plans aimed at enhancing member experience. These plans focus on providing personalized support, simplifying benefits, and offering meaningful choices to help members navigate healthcare confidently. As the enrollment period approaches, members are encouraged to evaluate their options for better healthcare management.
Read more →-ELV
Jul 30, 2026Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
Elevance Health is enhancing its connected cancer care model to provide better support for consumers throughout their health journeys. The initiative focuses on earlier support, personalized care navigation, and improved coordination of care. This enhancement aims to address the emotional and logistical challenges faced by cancer patients.
Read more →-ELV
Jul 15, 2026▼ -8.5%on this news
Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
Elevance Health, Inc. reported strong second quarter 2026 results that surpassed expectations, driven by effective execution and enhanced operational performance. The company has raised its full-year adjusted EPS guidance to a minimum of $27.00. This positive outlook reflects their commitment to investing in key areas such as medical cost management and member experience.
Read more →-ELV
Jul 6, 2026Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
Elevance Health has announced a conference call and webcast scheduled for July 15, 2026, to discuss its second quarter results for the year. This event aims to provide insights into the company's financial performance during that period. Further details regarding the call's agenda and participation will likely be shared closer to the date.
Read more →-ELV
Jun 29, 2026Elevance Health Foundation Invests $5.8 Million to Strengthen Behavioral Health Access Nationwide
Elevance Health Foundation has announced a $5.8 million investment aimed at improving access to behavioral health services across the United States. This initiative is designed to strengthen mental health support systems, reflecting the foundation's commitment to addressing behavioral health challenges. The funding will facilitate broader access to essential services nationwide.
Read more →-ELV
Jun 25, 2026New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
The article discusses a study conducted by Elevance Health's Public Policy Institute regarding payment disputes for planned procedures under the No Surprises Act. However, the content is limited and does not provide detailed findings or implications of the study. Further information is needed to understand the study's conclusions and its impact on healthcare policy.
Read more →-ELV
Jun 24, 2026Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
Thomas Carr Howe Middle School has launched a new fitness and strength training space through a partnership with Elevance Health and the Impact Fitness Foundation. This initiative aims to promote health and wellness among students. The collaboration reflects a commitment to enhancing physical education resources in schools.
Read more →-ELV
Jun 23, 2026Elevance Health Makes Clinical Review Faster, More Connected with Health OS
Elevance Health has introduced a new Health OS aimed at enhancing the clinical review process. This system is designed to make the review process faster and more interconnected. However, specific details about the features and benefits of Health OS are not provided in the article.
Read more →-ELV
Jun 17, 2026Elevance Health Announces $640 Million Investment in Affordable Housing Over the Past Five Years, Surpassing $1 Billion in Total Commitment Nationwide
Elevance Health has announced that it has invested $640 million in affordable housing over the past five years. This investment contributes to a total commitment of over $1 billion nationwide. The company aims to address housing challenges and improve community health outcomes through these efforts.
Read more →-ELV
Jun 15, 2026Elevance Health Makes Chronic Care Easier to Navigate With Connected, Personalized Support
Elevance Health has introduced a new initiative aimed at simplifying chronic care management. The program focuses on providing connected and personalized support to patients, enhancing their navigation through the healthcare system. This move is expected to improve patient experiences and outcomes in managing chronic conditions.
Read more →-ELV
Apr 22, 2026Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance
Elevance Health reported strong first quarter 2026 results, surpassing expectations and raising its full-year adjusted EPS guidance. The company experienced growth in operating revenue, primarily driven by higher premium yields. However, it also noted a decrease in operating gain and anticipated declines in certain membership segments, reflecting challenges in the Medicaid and Medicare Advantage areas.
Read more →-ELV
Oct 21, 2025ELEVANCE HEALTH REPORTS THIRD QUARTER 2025 RESULTS
Elevance Health, Inc. reported a 12% increase in third quarter operating revenue for 2025, reaching $50.1 billion, largely due to higher premium yields and growth in Medicare Advantage membership. Despite the revenue growth, operating gain and margins decreased, attributed to increased medical costs and ongoing Medicaid membership losses. The company's strategic focus remains on improving affordability and member experience, and it is actively investing in technology and workforce capabilities. Shareholder returns included a quarterly dividend and significant share repurchase activity.
Read more →-ELV
Apr 18, 2024EARNINGS RELEASE ELEVANCE HEALTH REPORTS FIRST QUARTER 2024 RESULTS 1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 1Q 2024 diluted EPS 1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS 2 of $10
Elevance Health (NYSE: ELV) reported its first-quarter results for 2024, showing an operating revenue of $42.3 billion, a modest increase compared to the same period last year. The company's diluted EPS increased significantly by 15.5% to $9.59. Despite challenges such as Medicaid membership attrition, Elevance is optimistic about expanding its Carelon services and has raised its full-year earnings outlook. Additionally, the company has established a partnership aimed at enhancing value-based care and healthcare delivery innovation.
Read more →-ELV
Jan 24, 2024E A R N I N G S R E L E A S E ELEVANCE HEALTH REPORTS RESULTS FOR FOURTH QUARTER AND FULL YEAR 2023; SETS FULL YEAR 2024 OUTLOOK 4Q 2023 operating revenue of $42.5 billion, up 7.0% from 4Q 2022; FY 2023 operating revenue
Elevance Health has released its earnings report for Q4 2023 and the full year, revealing strong performance with a 7% rise in operating revenue to $42.5 billion. The growth was attributed to higher premium and pharmacy product revenues. However, the company faced a decline in medical membership and a slight decrease in operating gain for the fourth quarter. The outlook for 2024 remains optimistic as Elevance continues to focus on innovation and customer experience.
Read more →-ELV
Oct 18, 2023ELEVANCE HEALTH REPORTS THIRD QUARTER 2023 RESULTS Third quarter GAAP net income was $5.45 per share, including net negative adjustment items of $3.54 per share. Adjusted net income was $8.99* per share. Operating gain,
Elevance Health, Inc. reported strong financial performance for the third quarter of 2023, highlighting a GAAP net income of $5.45 per share and an adjusted net income of $8.99 per share. However, the company experienced a drop in medical membership, with a decrease of 664,000 members attributed mainly to Medicaid attrition. Despite this, overall operating revenue grew by 7.2%, driven by higher premium revenues and the acquisition of BioPlus. The company also announced plans to enhance operational efficiency after a strategic review, which led to certain optimization charges.
Read more →-ELV
Aug 8, 2023Elevance Health Announces John Gallina to Retire as CFO Mark Kaye named Executive Vice President, Chief Financial Officer INDIANAPOLIS
Elevance Health has announced the retirement of John Gallina as CFO, effective later this year. Mark Kaye has been appointed as the new executive vice president and CFO, bringing significant financial experience from Moody's Corporation. Gallina will continue to support the company as a Special Advisor during the transition to ensure a seamless changeover in leadership. Elevance Health aims to sustain its commitment to improving community health through this transition.
Read more →-ELV
Jul 19, 2023P R E S S R E L E A S E ELEVANCE HEALTH REPORTS SECOND QUARTER 2023 RESULTS Second quarter GAAP net income was $7.79 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $9.04* p
Elevance Health, Inc. reported strong second-quarter results for 2023, showcasing double-digit growth in revenue and significant adjusted earnings. The company anticipates higher GAAP net income expectations for the year, bolstered by growing membership across key segments like Medicaid and Medicare. Despite a decrease in medical membership tied to eligibility redeterminations, the overall performance indicates a successful execution of strategic initiatives. The company's focus on optimizing existing businesses and investing in growth areas positions it positively for the remainder of 2023.
Read more →-ELV
Apr 19, 2023▼ -5.3%on this news
ELEVANCE HEALTH REPORTS FIRST QUARTER 2023 RESULTS First quarter GAAP net income was $8.30 per share, including net negative adjustment items of $1.16 per share. Adjusted net income was $9.46* per share. Operating revenu
Elevance Health, Inc. reported strong first quarter results for 2023, achieving a GAAP net income of $8.30 per share and an adjusted net income of $9.46 per share. The company's operating revenue rose by 10.6% to $41.9 billion, driven by growth in Medicaid, Medicare Advantage, and pharmacy products. Medical membership increased by approximately 1.3 million compared to the previous year, reflecting a robust demand for their services. Elevated expectations for future GAAP and adjusted net income indicate bullish market confidence.
Read more →-ELV
Jan 25, 2023ELEVANCE HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2022 RESULTS Fourth quarter and full year GAAP net income was $3.93 and $24.81 per share Fourth quarter and full year adjusted net income was $5.23* and
Elevance Health, Inc. reported robust financial results for the fourth quarter and full year 2022, showcasing significant growth in revenue and adjusted net income. The company experienced strong increases in membership, particularly within its Medicaid and Medicare Advantage sectors. While it anticipates continued growth, challenges in operating cash flow and investment portfolio losses may pose risks to its financial stability. Elevance Health also announced an increased dividend and an expansion of its share repurchase program.
Read more →About Elevance Health, Inc.
Headquarters220 VIRGINIA AVENUE, INDIANAPOLIS, IN, 46204
BIOPHARMAWATCH ELITE PLUS
Trade the next ELV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime